Pavmed (NSDQ:PAVM) today priced an underwritten public offering of 2,415,278 shares of its common stock at $1.80 per share. The New York City-based company said it would grant the offering’s underwriters a 45-day option to buy up to 362,292 additional shares of common stock to cover over-allotments. Pavmed expects to bring in $3.9 million in net […]
Pavmed
Pavmed registers $90m offering
Pavmed (NSDQ:PAVM) has registered for a nearly $90 million offering, saying it plans to float the rights to buy up to 14.6 million units. The New York City-based company said it would issue a single unit for each share of common stock. Each unit is slated to include one common share and a six-year Series Z warrant worth […]
Pavmed sets terms for warrants offering
Pavmed (NSDQ:PAVM) said today that it set the terms for a forthcoming rights offering, saying it plans to issue a single unit for each share of common stock. Each unit will include one common share and a six-year Series Z warrant worth $2.25 per share, redeemable at $3 each, the New York City-based company said. Last […]
Pavmed cuts warrant price again
Pavmed (NSDQ:PAVM) said today it would cut the cash exercise price of each of its Series W warrants from $2.50 to $2.00 apiece. This is the second price cut that Pavmed has given for its outstanding warrants. Each of the New York-based company’s outstanding warrants were exercisable at $5.00 apiece for one share of common stock […]
Pavmed offers warrants at half-price to raise cash for carpal tunnel syndrome device
Pavmed (NSDQ:PAVM) said this week that it plans to temporarily cut the exercise price of its outstanding Series W warrants in half. Each of the New York-based company’s outstanding warrants is currently exercisable at $5.00 apiece for one share of common stock. After Pavmed files tender offer materials, each warrant will have an exercise price of […]
Pavmed files FDA 510(k) for CarpX carpal tunnel device
Pavmed (NSDQ:PAVM) said today it filed a 510(k) application with the FDA for its CarpX minimally invasive device designed to treat carpal tunnel syndrome. The CarpX is a percutaneous device designed to allow the operating physician to relieve compression of the median nerve without a surgical incision. The system combines a balloon catheter with bipolar radio-frequency […]
Pavmed shares climb after Q3 EPS beat
Shares in Pavmed Inc. (NSDQ:PAVM) rose today after the medical device maker beat expectations on Wall Street with its third quarter results. The N.Y.-based company posted a net loss of -$5.37 million, or -40¢ per share, for the 3 months ended Sept. 30, for bottom-line loss of -178.5% compared with the same period last year. Get the […]
Pavmed to drop 510(k), pursue de novo pathway for PortIO infusion system
Pavmed Inc. (NSDQ:PAVM) plans to drop the 510(k) application for its PortIO intraosseous infusion system and instead pursue a de novo pathway for its device, according to a document the company filed with the SEC yesterday. The move is based on a recommendation from the FDA, the company said. Get the full story at our sister site, Drug […]
Pavmed beats Q2 EPS by a penny
Medical device maker Pavmed Inc. (NSDQ:PAVM) topped expectations on Wall Street with its second quarter results today. The New York-based company posted a net loss of -$989,707, or -8¢ per share, for the 3 months ended June 30, for bottom-line growth of 25% compared with the same period last year. Get the full story at our sister […]
Pavmed raises $5m in private placement
Pavmed (NSDQ:PAVM) said today it closed a $5 million private placement through the sale of senior notes and Series S warrants. Funding in the private placement came from Scopia Holdings, who elected Dr. David Battleman to New York-based Pavmed’s board of directors as part of the financing. “I look forward to joining the PAVmed team as a […]
Pavmed files for $23m private placement
Pavmed (NSDQ:PAVMU) registered for an upcoming private placement, looking to raise approximately $23.4 million, according to an SEC filing posted this week. The New York-based company will look to offer registered derivative securities from conversion of preferred stock, 10 years potential dividends for preferred stock, exchange of Series A warrants for public warrants and exercise of all warrants, according […]